Is Boston Scientific (BSX) Becoming the Leading MedTech Growth Story?

Core Insights - Boston Scientific Corp. (NYSE:BSX) is recognized as a strong investment opportunity by Citadel LLC, with a reiterated price target of $115 and a Buy rating from TD Cowen analyst Josh Jennings following the company's robust Q3 2025 results [1][2]. Financial Performance - The company achieved a notable 15.3% organic growth in Q3 2025, surpassing its own guidance, primarily driven by strong performance in the Electrophysiology and Watchman businesses within the Cardiology segment [2]. - This organic growth contributed to stronger sales and earnings per share (EPS), allowing the company to exceed market expectations [2]. Future Outlook - Boston Scientific has raised its guidance for growth and profitability for the third time this year, projecting organic sales growth of approximately 20% on a reported basis and 15.5% on an organic basis for 2025, an increase from the previous guidance of 18%-19% and 14%-15% respectively [3]. - The company also maintains a positive outlook on margins, reinforcing a bullish perspective on its future performance [3]. Company Overview - Boston Scientific is a global medical technology company that develops, manufactures, and markets a diverse range of medical devices aimed at diagnosing and treating complex cardiovascular, respiratory, oncological, neurological, and urological diseases and conditions [4].